{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:07:19Z","timestamp":1792804039870,"version":"4.5.0"},"reference-count":210,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.jconrel.2007.10.027","type":"journal-article","created":{"date-parts":[[2007,12,5]],"date-time":"2007-12-05T02:18:08Z","timestamp":1196821088000},"page":"210-227","source":"Crossref","is-referenced-by-count":189,"title":["Delivery systems to increase the selectivity of antibiotics in phagocytic cells"],"prefix":"10.1016","volume":"125","author":[{"given":"Elsa","family":"Briones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Isabel Colino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Lanao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2007.10.027_bib1","series-title":"Phagocytosis of Bacteria and Bacterial Pathogenicity","author":"Ernst","year":"2006"},{"issue":"41","key":"10.1016\/j.jconrel.2007.10.027_bib2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/2101131a0","article-title":"Protection of phagocytized bacteria from the killing action of antibiotics","volume":"210","author":"Holmes","year":"1966","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0891-5520(03)00066-7","article-title":"Intracellular pharmacodynamics of antibiotics","volume":"17","author":"Carryn","year":"2003","journal-title":"Infect. Dis. Clin. North. Am."},{"issue":"8","key":"10.1016\/j.jconrel.2007.10.027_bib4","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/AAC.40.8.1893","article-title":"Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium\u2013M. intracellulare complex infection","volume":"40","author":"Mehta","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2007.10.027_bib5","first-page":"100","article-title":"Uptake of antibiotics by phagocytic cells: study methods and therapeutic implications","volume":"8","author":"Reinoso","year":"1995","journal-title":"Rev. Esp. Quimioterap."},{"key":"10.1016\/j.jconrel.2007.10.027_bib6","series-title":"Phagocytosis of Bacteria and Bacterial Pathogenicity","first-page":"4","article-title":"Phagocytosis: receptors and biology","author":"Hazenbos","year":"2006"},{"issue":"1-3","key":"10.1016\/j.jconrel.2007.10.027_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0168-3659(01)00549-1","article-title":"Targeting to macrophages: role of physicochemical properties of particulate carriers\u2013liposomes and microspheres\u2013on the phagocytosis by macrophages","volume":"79","author":"Ahsan","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2007.10.027_bib8","series-title":"Antimicrobial Therapy","first-page":"513","article-title":"White cells","author":"Klempner","year":"1984"},{"issue":"11","key":"10.1016\/j.jconrel.2007.10.027_bib9","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1128\/AAC.45.11.2977-2986.2001","article-title":"Use of aminoglycosides in treatment of infections due to intracellular bacteria","volume":"45","author":"Maurin","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/AAC.33.3.277","article-title":"In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection","volume":"33","author":"Gladue","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1128\/AAC.34.6.1056","article-title":"Intracellular accumulation of azithromycin by cultured human fibroblasts","volume":"34","author":"Gladue","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1568012033354612","article-title":"Interactions between antimicrobial agents, phagocytic cells and bacteria","volume":"2","author":"Hand","year":"2003","journal-title":"Curr. Med. Chem. - Anti-Infec. Agents"},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1128\/AAC.21.3.373","article-title":"Antibiotic entry into human polymorphonuclear leukocytes","volume":"21","author":"Prokesch","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.jconrel.2007.10.027_bib14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.31.10.1553","article-title":"Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes","volume":"31","author":"Hand","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib15","first-page":"218","article-title":"Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives","volume":"9","author":"Van Bambeke","year":"2006","journal-title":"Curr. Opin. Drug Discov. Devel."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/AAC.50.3.841-851.2006","article-title":"Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages","volume":"50","author":"Barcia-Macay","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"B","key":"10.1016\/j.jconrel.2007.10.027_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jac\/26.suppl_B.27","article-title":"Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages","volume":"26","author":"Carlier","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.jconrel.2007.10.027_bib18","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1128\/AAC.40.12.2756","article-title":"Uptake and intracellular activity of AM-1155 in phagocytic cells","volume":"40","author":"Yamamoto","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2007.10.027_bib19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/infdis\/169.2.330","article-title":"Phagolysosomal alkalinization and intracellular killing of Staphylococcus aureus by amikacin","volume":"169","author":"Maurin","year":"1994","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2007.10.027_bib20","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1128\/AAC.43.9.2268","article-title":"In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model","volume":"43","author":"Kutlin","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.jconrel.2007.10.027_bib21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/infdis\/144.5.472","article-title":"Clindamycin uptake by human neutrophils","volume":"144","author":"Klempner","year":"1981","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/infdis\/153.3.593","article-title":"An in vitro investigation of the intracellular bioactivity of amoxicillin, clindamycin, and erythromycin for Staphylococcus aureus","volume":"153","author":"Anderson","year":"1986","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2007.10.027_bib23","first-page":"725","article-title":"Cellular uptake of clindamycin and lincomycin","volume":"65","author":"Easmon","year":"1984","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.jconrel.2007.10.027_bib24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/AAC.25.6.735","article-title":"Antibiotic action on phagocytosed bacteria measured by a new method for determining viable bacteria","volume":"25","author":"Vosbeck","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.jconrel.2007.10.027_bib25","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1128\/AAC.42.10.2511","article-title":"Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes","volume":"42","author":"Lutwyche","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.jconrel.2007.10.027_bib26","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/AAC.43.7.1638","article-title":"Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine","volume":"43","author":"Adams","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2007.10.027_bib27","first-page":"483","article-title":"Effect of liposome composition and cholesterol on the cellular uptake of stavudine by human monocyte\/macrophages","volume":"5","author":"Katragadda","year":"2000","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/107175400455137","article-title":"Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo","volume":"7","author":"Sinha","year":"2000","journal-title":"Drug Deliv."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/48.3.333","article-title":"Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies","volume":"48","author":"Schiffelers","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0928-0987(01)00218-4","article-title":"In vitro phagocytosis and monocyte\u2013macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres","volume":"15","author":"Prior","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0939-6411(98)00038-1","article-title":"Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats","volume":"46","author":"Roser","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.jconrel.2007.10.027_bib32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1470-8744.1990.tb00119.x","article-title":"The future of liposomal drug delivery","volume":"12","author":"Szoka","year":"1990","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0923-2516(97)89906-2","article-title":"Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection","volume":"148","author":"Grimaldi","year":"1997","journal-title":"Res. Virol."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/AAC.41.1.17","article-title":"Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection","volume":"41","author":"Kansal","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.jconrel.2007.10.027_bib35","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s100960050189","article-title":"Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis","volume":"17","author":"Whitehead","year":"1998","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.jconrel.2007.10.027_bib36","series-title":"Nanoparticulates as Drug Carriers","author":"Torchilin","year":"2006"},{"key":"10.1016\/j.jconrel.2007.10.027_bib37","series-title":"Nanoparticulates as Drug Carriers","first-page":"463","article-title":"Nanoparticulate drug delivery to the reticuloendothelial system and to associated disorders","author":"Basu","year":"2006"},{"key":"10.1016\/j.jconrel.2007.10.027_bib38","series-title":"Nanoparticulates as Drug Carriers","first-page":"697","article-title":"Pharmaceutical nanocarriers in treatment and imaging of infection","author":"Schiffelers","year":"2006"},{"key":"10.1016\/j.jconrel.2007.10.027_bib39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/3-540-36488-9_6","article-title":"Intracellular delivery of drugs to macrophages","volume":"84","author":"Mukhopadhyay","year":"2003","journal-title":"Adv. Biochem. Engin\/Biotechnol."},{"key":"10.1016\/j.jconrel.2007.10.027_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1573413052953110","article-title":"Nanosystems in drug targeting: opportunities and challenges","volume":"1","author":"Vasir","year":"2005","journal-title":"Curr. Nanosci."},{"key":"10.1016\/j.jconrel.2007.10.027_bib41","series-title":"Nanoparticulates as Drug Carriers","first-page":"255","article-title":"Nanocapsules: preparation, characterization and therapeutic applications","author":"Gref","year":"2006"},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0169-409X(99)00061-7","article-title":"Tuftsin-bearing liposomes in treatment of macrophage-based infections","volume":"41","author":"Agrawal","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib43","doi-asserted-by":"crossref","first-page":"639","DOI":"10.18388\/abp.2000_3985","article-title":"Liposomal drug delivery, a novel approach: PLARosomes","volume":"47","author":"Kozubek","year":"2000","journal-title":"Acta Biochim. Pol."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.2042-7158.1991.tb06657.x","article-title":"A simple method for the preparation of liposomes for pharmaceutical applications: characterization of the liposomes","volume":"43","author":"Perrett","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"issue":"1-2","key":"10.1016\/j.jconrel.2007.10.027_bib45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2006.08.044","article-title":"Multivariate toxicity screening of liposomal formulations on a human buccal cell line","volume":"330","author":"Smistad","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2007.10.027_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/107175400266777","article-title":"Comparison of the effects of dimyristoyl and soya phosphatidylcholine liposomes on human fibroblasts","volume":"7","author":"Berrocal","year":"2000","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0014-4827(87)90262-X","article-title":"Toxicity of non-drug-containing liposomes for cultured human cells","volume":"171","author":"Mayhew","year":"1987","journal-title":"Exp. Cell. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0005-2736(97)00126-0","article-title":"Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells","volume":"1329","author":"Filion","year":"1997","journal-title":"Biochim. Biophys. Acta."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib49","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0022-510X(77)90104-6","article-title":"Liposome toxicity in the mouse central nervous system","volume":"31","author":"Adams","year":"1977","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2007.10.027_bib50","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1097\/00000542-199505000-00014","article-title":"Touch-evoked agitation produced by spinally administered phospholipid emulsion and liposomes in rats. Structure-activity relation","volume":"82","author":"Yanez","year":"1995","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib51","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/clind\/15.4.654","article-title":"Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides","volume":"15","author":"Karlowsky","year":"1992","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib52","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1128\/AAC.44.3.533-539.2000","article-title":"Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar typhimurium intracellular infection model","volume":"44","author":"Cordeiro","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2007.10.027_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0076-6879(05)91016-1","article-title":"Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections","volume":"391","author":"Gupta","year":"2005","journal-title":"Methods Enzymol."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib54","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/AAC.40.1.146","article-title":"Effect of composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortus","volume":"40","author":"Vitas","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib55","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1128\/AAC.40.6.1467","article-title":"Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes\/macrophages in vitro","volume":"40","author":"Bender","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1-3","key":"10.1016\/j.jconrel.2007.10.027_bib56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0168-3659(97)00105-3","article-title":"Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats","volume":"50","author":"L\u00f6benberg","year":"1998","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2007.10.027_bib57","first-page":"31","article-title":"Controlled release of antiretroviral drugs","volume":"2","author":"Von Briesen","year":"2000","journal-title":"AIDS Rev."},{"key":"10.1016\/j.jconrel.2007.10.027_bib58","series-title":"Nanoparticulates as Drug Carriers","first-page":"29","article-title":"Polymeric nanoparticles as drug carriers and controlled release implant devices","author":"Moghimi","year":"2006"},{"issue":"23","key":"10.1016\/j.jconrel.2007.10.027_bib59","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/S0142-9612(00)00115-0","article-title":"The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices","volume":"21","author":"Jain","year":"2000","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0924-8579(99)00121-1","article-title":"Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications","volume":"13","author":"Pinto-Alphandary","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-5173(99)00448-2","article-title":"Gentamicin encapsulation in PLA\/PLGA microspheres in view of treating Brucella infections","volume":"196","author":"Prior","year":"2000","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s000180300002","article-title":"Colloidal drug carriers: achievements and perspectives","volume":"60","author":"Barratt","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib63","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery \u2014 a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"9","key":"10.1016\/j.jconrel.2007.10.027_bib64","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1248\/bpb.29.1790","article-title":"Nanocarriers: promising vehicle for bioactive drugs","volume":"29","author":"Rawat","year":"2006","journal-title":"Biol. Pharm. Bull."},{"issue":"5761","key":"10.1016\/j.jconrel.2007.10.027_bib65","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1114397","article-title":"Toxic potential of materials at the nanolevel","volume":"311","author":"Nel","year":"2006","journal-title":"Science"},{"issue":"2-3","key":"10.1016\/j.jconrel.2007.10.027_bib66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0378-5173(86)90081-5","article-title":"Evaluation of poly(lactic acid) as a biodegradable drug delivery system for parenteral administration","volume":"30","author":"Smith","year":"1986","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2007.10.027_bib67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0378-5173(96)04539-5","article-title":"Cytotoxicity of magnetide-loaded polylactide, polylactide\/glycolide particles and solid lipid nanoparticles","volume":"138","author":"M\u00fcller","year":"1996","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2007.10.027_bib68","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0939-6411(97)00172-0","article-title":"Spray-drying of solid lipid nanoparticles (SLN\u2122)","volume":"46","author":"Freitas","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"23","key":"10.1016\/j.jconrel.2007.10.027_bib69","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1016\/S0142-9612(02)00216-8","article-title":"Evaluation of cationic solid lipid microparticles as synthetic carriers for the targeted delivery of macromolecules to phagocytic antigen-presenting cells","volume":"23","author":"Erni","year":"2002","journal-title":"Biomaterials"},{"issue":"1-2","key":"10.1016\/j.jconrel.2007.10.027_bib70","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0168-3659(02)00258-4","article-title":"New lipid nanocapsules exhibit sustained release properties for amiodarone","volume":"84","author":"Lamprecht","year":"2002","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib71","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1007\/s00436-002-0769-2","article-title":"Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs","volume":"90","author":"Kayser","year":"2003","journal-title":"Parasitol. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2007.10.027_bib72","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1023\/B:PHAM.0000045229.87844.21","article-title":"Novel long-circulating lipid nanocapsules","volume":"21","author":"Hoarau","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2007.10.027_bib73","series-title":"Nanoparticulates as Drug Carriers","first-page":"187","article-title":"Solid lipid nanoparticles as drug carriers","author":"M\u00e4der","year":"2006"},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","article-title":"Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future","volume":"47","author":"M\u00fcller","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.jconrel.2007.10.027_bib75","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1128\/AAC.43.9.2209","article-title":"Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives","volume":"43","author":"Golenser","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.jconrel.2007.10.027_bib76","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1128\/AAC.47.11.3435-3441.2003","article-title":"Synthesis, degradation, and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin","volume":"47","author":"Roseeuw","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib77","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2003.09.012","article-title":"Targetable water-soluble polymer-drug conjugates for the treatment of visceral leishmaniasis","volume":"94","author":"Nan","year":"2004","journal-title":"J. Control. Release."},{"issue":"1-2","key":"10.1016\/j.jconrel.2007.10.027_bib78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1163\/156856206774879171","article-title":"Dendrimers for pharmaceutical and biomedical applications","volume":"17","author":"Yang","year":"2006","journal-title":"J. Biomater. Sci. Polym. Ed."},{"issue":"15","key":"10.1016\/j.jconrel.2007.10.027_bib79","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.addr.2005.09.018","article-title":"Dendrimers in biomedical applications-reflections on the field","volume":"57","author":"Svenson","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2007.10.027_bib80","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bbagen.2006.12.007","article-title":"Targeting potencial and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer","volume":"1770","author":"Dutta","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.jconrel.2007.10.027_bib81","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/10611860600825159","article-title":"Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers","volume":"14","author":"Kumar","year":"2006","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib82","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11095-005-9396-9","article-title":"PEGylated peptide dendrimeric carriers for the delivery of antimalarial drug chloroquine phosphate","volume":"23","author":"Bhadra","year":"2006","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib83","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1211\/0022357055803","article-title":"Mechanism of cell death induced by cationic dendrimers in RAW 264.7 murine macrophage-like cells","volume":"57","author":"Kuo","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"issue":"15","key":"10.1016\/j.jconrel.2007.10.027_bib84","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.addr.2005.09.019","article-title":"Dendrimer biocompatibility and toxicity","volume":"57","author":"Duncan","year":"2005","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"2-3","key":"10.1016\/j.jconrel.2007.10.027_bib85","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0168-3659(98)00052-2","article-title":"Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles","volume":"55","author":"Kader","year":"1998","journal-title":"J. Control. Release."},{"key":"10.1016\/j.jconrel.2007.10.027_bib86","series-title":"Nanoparticulates as Drug Carriers","first-page":"173","article-title":"Lipoproteins as pharmaceutical carriers","author":"Liu","year":"2006"},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib87","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0168-3659(00)00319-9","article-title":"Enhanced delivery of AZT to macrophages via acetylated LDL","volume":"69","author":"Hu","year":"2000","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib88","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/bbrc.1997.7625","article-title":"Low density lipoproteins as drug carriers in the therapy of macrophage-associated diseases","volume":"240","author":"Mankertz","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1-3","key":"10.1016\/j.jconrel.2007.10.027_bib89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0168-3659(01)00536-3","article-title":"Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells","volume":"80","author":"Kader","year":"2002","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib90","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0009-3084(03)00002-1","article-title":"Structural characterisation of nucleoside loaded low density lipoprotein as a main criterion for the applicability as drug delivery system","volume":"123","author":"Hammel","year":"2003","journal-title":"Chem. Phys. Lipids."},{"key":"10.1016\/j.jconrel.2007.10.027_bib91","series-title":"Nanoparticulates as Drug Carriers","first-page":"329","article-title":"Cells and cell ghosts as drug carriers","author":"Lanao","year":"2006"},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib92","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/02652049209021250","article-title":"Erythrocyte based delivery system of primaquine: in vitro characterization","volume":"9","author":"Talwar","year":"1992","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2007.10.027_bib93","first-page":"269","article-title":"The use of resealed erythrocytes as carriers and bioreactors","volume":"vol. 326","author":"Chiarantini","year":"1992"},{"issue":"11","key":"10.1016\/j.jconrel.2007.10.027_bib94","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.gt.3301758","article-title":"Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides","volume":"9","author":"Magnani","year":"2002","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib95","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/713840329","article-title":"Carrier erythrocytes: an overview","volume":"10","author":"Hamidi","year":"2003","journal-title":"Drug Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib96","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1073\/pnas.86.6.2040","article-title":"Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model","volume":"86","author":"Zocchi","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jconrel.2007.10.027_bib97","first-page":"291","article-title":"The use of resealed erythrocytes as carriers and bioreactors","volume":"vol. 326","author":"Gasparini","year":"1992"},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib98","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/clpt.1986.180","article-title":"In vivo clearance of antibody-sensitized human drug carrier erythrocytes","volume":"40","author":"Eichler","year":"1986","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2007.10.027_bib99","first-page":"215","article-title":"Erythrocytes as carriers of new anti-opioid prodrugs: in vitro studies","volume":"326","author":"Noel-Hocquet","year":"1992","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/CS19980229","article-title":"Survival of human carrier erythrocytes in vivo","volume":"96","author":"Bax","year":"1999","journal-title":"Clin. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib101","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.2830090303","article-title":"Erythrocytes as carriers of chemotherapeutic agents for targeting the reticuloendothelial system","volume":"9","author":"Lynch","year":"1980","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib102","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2003.11.018","article-title":"Drug, enzyme and peptide delivery using erythrocytes as carriers","volume":"95","author":"Mill\u00e1n","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2007.10.027_bib103","first-page":"275","article-title":"Engineered erythrocytes as a drug delivery system","volume":"59","author":"Jain","year":"1997","journal-title":"Indian J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2007.10.027_bib104","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1046\/j.1365-2346.2000.00741.x","article-title":"A central venous catheter coated with benzalkonium chloride for the prevention of catheter-related microbial colonization","volume":"17","author":"Moss","year":"2000","journal-title":"Eur. J. Anaesthesiol."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0955-3886(00)00128-4","article-title":"Cellular contamination of plasma collected with various apheresis systems","volume":"24","author":"Valbonesi","year":"2001","journal-title":"Transfus. Apheresis Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib106","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1473-0502(01)00067-2","article-title":"Current status of bacterial contamination of autologous blood for transfusion","volume":"24","author":"Sugai","year":"2001","journal-title":"Transfus. Apheresis Sci."},{"key":"10.1016\/j.jconrel.2007.10.027_bib107","first-page":"283","article-title":"Bacterial contamination of cellular blood components. A retrospective review at a large cancer center","volume":"25","author":"\u00c1lvarez","year":"1995","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib108","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jac\/dkg290","article-title":"Accumulation and activity of cethromycin (ABT-773) within human polymorphonuclear leucocytes","volume":"52","author":"Garcia","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.jconrel.2007.10.027_bib109","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/AAC.37.12.2557","article-title":"Interactions of dirithromycin with human polymorphonuclear leukocytes","volume":"37","author":"Hand","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.jconrel.2007.10.027_bib110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0924-8579(01)00430-7","article-title":"Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes","volume":"18","author":"Hand","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5","key":"10.1016\/j.jconrel.2007.10.027_bib111","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1189\/jlb.1005550","article-title":"Recognition ligands on apoptotic cells: a perspective","volume":"79","author":"Gardai","year":"2006","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"10.1016\/j.jconrel.2007.10.027_bib112","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1189\/jlb.70.5.708","article-title":"Uptake of apoptotic leukocytes by synovial lining macrophages inhibits immune complex-mediated arthritis","volume":"70","author":"Van Lent","year":"2001","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib113","first-page":"151","article-title":"Sealed bacterial ghosts\u2014novel targeting vehicles for advanced drug delivery of water-soluble substances","volume":"11","author":"Paukner","year":"2003","journal-title":"J. Drug Target."},{"issue":"1-2","key":"10.1016\/j.jconrel.2007.10.027_bib114","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-3659(99)00099-1","article-title":"Bacterial ghosts as drug carrier and targeting vehicles","volume":"61","author":"Huter","year":"1999","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib115","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/AAC.34.6.967","article-title":"Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice","volume":"34","author":"Klemens","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib116","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1128\/AAC.34.2.343","article-title":"Successful treatment using gentamicin liposomes of Salmonella dublin infections in mice","volume":"34","author":"Fierer","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib117","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.42.2.459","article-title":"Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection","volume":"42","author":"Leitzke","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.jconrel.2007.10.027_bib118","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1128\/AAC.39.9.2104","article-title":"Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection","volume":"39","author":"Oh","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib119","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/1381612023395808","article-title":"Design of anti-bacterial drug and anti-mycobacterial drug for drug delivery system","volume":"8","author":"Yanagihara","year":"2002","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1128\/AAC.42.1.45","article-title":"Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation","volume":"42","author":"Webb","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib121","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1128\/AAC.38.3.523","article-title":"Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium\u2013M. intracellulare complex in human macrophages","volume":"38","author":"Onyeji","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.jconrel.2007.10.027_bib122","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1128\/AAC.40.11.2618","article-title":"Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin","volume":"40","author":"Duzgunes","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib123","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2003.08.017","article-title":"Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages","volume":"269","author":"Vyas","year":"2004","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib124","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.41.6.1211","article-title":"Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice","volume":"41","author":"Deol","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.jconrel.2007.10.027_bib125","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1128\/AAC.40.11.2545","article-title":"Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium\u2013Mycobacterium intracellulare complex after liposome encapsulation","volume":"40","author":"G\u00f3mez-Flores","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib126","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0378-5173(02)00552-5","article-title":"Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages","volume":"250","author":"Salem","year":"2003","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.jconrel.2007.10.027_bib127","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1128\/AAC.32.10.1560","article-title":"Effect of lipid composition on activity of liposome-entrapped ampicillin against intracellular Listeria monocytogenes","volume":"32","author":"Bakker-Woudenberg","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/10611860290007513","article-title":"Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters","volume":"10","author":"Agrawal","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2007.10.027_bib129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0014-5793(93)81760-W","article-title":"Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis","volume":"326","author":"Owais","year":"1993","journal-title":"FEBS Letters."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.26.2.170","article-title":"Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice","volume":"26","author":"Tremblay","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.jconrel.2007.10.027_bib131","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/AAC.33.9.1544","article-title":"Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice","volume":"33","author":"Gondal","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.jconrel.2007.10.027_bib132","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/infdis\/145.2.748","article-title":"Treatment of murine cryptococcosis with liposome-associated amphotericin B","volume":"145","author":"Graybill","year":"1982","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.jconrel.2007.10.027_bib133","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1164\/arrd.1982.125.5.610","article-title":"Amphotericin B in liposomes: a novel therapy for histoplasmosis","volume":"125","author":"Taylor","year":"1982","journal-title":"Am. Rev. Respir. Dis."},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib134","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jac\/dki307","article-title":"Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice","volume":"56","author":"Khan","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib135","first-page":"231","article-title":"Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin-beta complexed with different chemically modified beta-ciclodextrins","volume":"6","author":"Chakraborty","year":"2003","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2007.10.027_bib136","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1128\/AAC.42.9.2437","article-title":"Activity of liposomal amphotericin B with prolonged circulation in blood versus those of AmBisome and fungizone against intracellular Candida albicans in murine peritoneal macrophages","volume":"42","author":"van Etten","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1-2","key":"10.1016\/j.jconrel.2007.10.027_bib137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(00)00522-6","article-title":"Ligand directed macrophage targeting of amphotericin B loaded liposomes","volume":"210","author":"Vyas","year":"2000","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.jconrel.2007.10.027_bib138","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1128\/AAC.41.8.1731","article-title":"Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model","volume":"41","author":"Paul","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.jconrel.2007.10.027_bib139","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1128\/AAC.31.12.1897","article-title":"Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis","volume":"31","author":"Mehta","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.jconrel.2007.10.027_bib140","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1128\/AAC.31.12.1901","article-title":"Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections","volume":"31","author":"Mehta","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib141","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1128\/AAC.42.6.1412","article-title":"Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations","volume":"42","author":"Johnson","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.jconrel.2007.10.027_bib142","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1128\/AAC.43.5.1264","article-title":"Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole","volume":"43","author":"Oakley","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib143","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.jconrel.2007.10.027_bib144","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1128\/AAC.41.10.2238","article-title":"Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice","volume":"41","author":"Wallace","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib145","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/jac\/dki454","article-title":"Enhanced efficacy of pH-sensitive nystatin liposomes against Cryptococcus neoformans in murine model","volume":"57","author":"Nasti","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib146","first-page":"90","article-title":"In vitro activity of a liposomal nystatin formulation (Nyotran) against Cryptococcus neoformans","volume":"17","author":"Alonso-Vargas","year":"2000","journal-title":"Rev. Iberoam. Micol."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib147","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/jac\/dkh522","article-title":"Enhanced anticryptococcal activity of chloroquine in phosphatidylserine-containing liposomes in a murine model","volume":"55","author":"Khan","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.jconrel.2007.10.027_bib148","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1128\/AAC.42.10.2722","article-title":"Visceral leishmaniasis in the BALB\/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B","volume":"42","author":"Mullen","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib149","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jac\/dkh281","article-title":"Targeting Leishmania chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine","volume":"54","author":"Tempone","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/38.1.145","article-title":"Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes","volume":"38","author":"Banerjee","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib151","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jac\/44.6.791","article-title":"Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms","volume":"44","author":"Medda","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib152","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1128\/AAC.42.2.348","article-title":"A novel peptide-grafted liposomal delivery system targeted to macrophages","volume":"42","author":"Banerjee","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib153","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0378-5173(99)00016-2","article-title":"Liposomes as carriers of the antiretroviral agent dideoxycytidine-5\u2032-triphosphate","volume":"180","author":"Oussoren","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2007.10.027_bib154","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/382048","article-title":"Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis","volume":"189","author":"Mukherjee","year":"2004","journal-title":"J. Infect. Dis."},{"issue":"9-10","key":"10.1016\/j.jconrel.2007.10.027_bib155","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1166\/jnn.2006.478","article-title":"Nanocarriers with gentamicin to treat intracellular pathogens","volume":"6","author":"Lecaroz","year":"2006","journal-title":"J. Nanosci. Nanotechnol."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib156","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/jac\/dkl257","article-title":"Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin","volume":"58","author":"Lecaroz","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib157","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jac\/37.1.105","article-title":"Intracellular distribution of ampicillin in murine macrophages infected with Salmonella typhimurium and treated with (3H)ampicillin-loaded nanoparticles","volume":"37","author":"Balland","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.jconrel.2007.10.027_bib158","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1128\/AAC.42.10.2682","article-title":"Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages","volume":"42","author":"Barrow","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.jconrel.2007.10.027_bib159","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1023\/A:1007527204887","article-title":"Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization","volume":"17","author":"O'Hara","year":"2000","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.jconrel.2007.10.027_bib160","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1023\/A:1013094112861","article-title":"Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model","volume":"18","author":"Su\u00e1rez","year":"2001","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib161","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1128\/AAC.44.4.898-904.2000","article-title":"Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats","volume":"44","author":"Echevarria","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib162","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jac\/dkg351","article-title":"Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice","volume":"52","author":"Espuelas","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"issue":"1-2","key":"10.1016\/j.jconrel.2007.10.027_bib163","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0378-5173(03)00404-6","article-title":"A novel delivery system for amphotericin B with lipid nano-sphere (LNS)","volume":"265","author":"Fukui","year":"2003","journal-title":"Int. J. Pharm."},{"issue":"1-2","key":"10.1016\/j.jconrel.2007.10.027_bib164","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2003.08.002","article-title":"Comparison of LNS\u2013AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations","volume":"267","author":"Fukui","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2007.10.027_bib165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0939-6411(97)00078-7","article-title":"Body distribution of azidothymidine bound to nanoparticles after oral administration","volume":"44","author":"L\u00f6benberg","year":"1997","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib166","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0378-5173(99)00434-2","article-title":"Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages","volume":"196","author":"Kayser","year":"2000","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.jconrel.2007.10.027_bib167","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1128\/AAC.43.8.1975","article-title":"A novel injectable water-soluble amphotericin B-arabinogalactan conjugate","volume":"43","author":"Falk","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib168","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0925-4439(96)00059-2","article-title":"Selective endocytosis of fluorothymidine and azidothymidine coupled to LDL into HIV infected mononuclear cells","volume":"1317","author":"Mankertz","year":"1996","journal-title":"Biochim. Biophys. Acta."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib169","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0166-3542(96)01011-X","article-title":"Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: efficiency metabolism and activity against human immunodeficiency virus or herpes simplex virus","volume":"33","author":"Perno","year":"1997","journal-title":"Antiviral Res."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib170","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/47.6.819","article-title":"Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus","volume":"47","author":"Rossi","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib171","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0166-3542(00)00101-7","article-title":"A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus","volume":"47","author":"Franchetti","year":"2000","journal-title":"Antiviral Res."},{"issue":"14","key":"10.1016\/j.jconrel.2007.10.027_bib172","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1073\/pnas.89.14.6477","article-title":"Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies","volume":"89","author":"Magnani","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1-2","key":"10.1016\/j.jconrel.2007.10.027_bib173","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0165-2427(94)07014-X","article-title":"FIV infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine 5\u2032-triphosphate","volume":"46","author":"Magnani","year":"1995","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib174","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/bbrc.1996.0349","article-title":"Azidothymidine homodinucleotide-loaded erythrocytes and bioreactors for slow delivery of the antiretroviral drug azidothymidine","volume":"220","author":"Benatti","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.jconrel.2007.10.027_bib175","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1128\/AAC.37.12.2584","article-title":"In vitro activities of free and liposomal drugs against Mycobacterium avium\u2013M. intracellulare complex and M. tuberculosis","volume":"37","author":"Mehta","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4-5","key":"10.1016\/j.jconrel.2007.10.027_bib176","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0171-2985(11)80465-1","article-title":"Use of liposome preparation to treat mycobacterial infections","volume":"191","author":"Bermudez","year":"1994","journal-title":"Immunobiology"},{"key":"10.1016\/j.jconrel.2007.10.027_bib177","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0076-6879(05)91015-X","article-title":"Liposome-encapsulated antibiotics","volume":"391","author":"Salem","year":"2005","journal-title":"Methods Enzymol."},{"issue":"26","key":"10.1016\/j.jconrel.2007.10.027_bib178","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.2174\/1381612043383250","article-title":"Liposome technology for drug delivery against mycobacterial infections","volume":"10","author":"Khuller","year":"2004","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib179","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jac\/dkf221","article-title":"Comparison of the antibacterial activities of ampicillin, ciprofloxacin, clarithromycin, telithromycin and quinupristin\/dalfopristin against intracellular non-typeable Haemophilus influenzae","volume":"50","author":"Ahren","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib180","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jac\/dki027","article-title":"Antitubercular inhaled therapy: opportunities, progress and challenges","volume":"55","author":"Pandey","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"10.1016\/j.jconrel.2007.10.027_bib181","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1128\/AAC.42.10.2569","article-title":"Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level","volume":"42","author":"Jahn","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1-2","key":"10.1016\/j.jconrel.2007.10.027_bib182","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0378-5173(00)00663-3","article-title":"Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients","volume":"213","author":"Eldem","year":"2001","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib183","first-page":"67","article-title":"Development of liposomal polyene antibiotics: an historical perspective","volume":"6","author":"Agatha","year":"2003","journal-title":"J. Pharm. Pharmaceut. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib184","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1381612023395916","article-title":"Drug delivery system of anti-fungal and parasitic agents","volume":"8","author":"Maesaki","year":"2002","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib185","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2174\/1381612023395871","article-title":"Lipid formulation as a drug carrier for drug delivery","volume":"8","author":"Tomii","year":"2002","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib186","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/14787210.3.2.167","article-title":"Liposomal amphotericin B: clinical experience and perspectives","volume":"3","author":"Gibbs","year":"2005","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib187","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/AAC.44.3.540-545.2000","article-title":"Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats","volume":"44","author":"van Etten","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2007.10.027_bib188","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0169-409X(96)00496-6","article-title":"Supramolecular lipidic drug delivery systems: from laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B","volume":"24","author":"Hillery","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib189","first-page":"S5","article-title":"Liposomal drug delivery system from laboratory to clinic","volume":"51","author":"Kshirsagar","year":"2005","journal-title":"J. Postgrad. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib190","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/jac\/36.6.961","article-title":"Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans","volume":"36","author":"van Etten","year":"1995","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib191","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/49.suppl_1.21","article-title":"AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience","volume":"49","author":"Adler-Moore","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib192","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.42.4.899","article-title":"Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis","volume":"42","author":"Clemons","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.jconrel.2007.10.027_bib193","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1128\/AAC.45.12.3555-3559.2001","article-title":"Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani","volume":"45","author":"Carter","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib194","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/AAC.41.4.752","article-title":"Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis","volume":"41","author":"Yardley","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0924-8579(99)00133-8","article-title":"A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis","volume":"13","author":"Yardley","year":"2000","journal-title":"Int. J. Antimicrob. Agents."},{"issue":"5","key":"10.1016\/j.jconrel.2007.10.027_bib196","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1128\/AAC.40.5.1214","article-title":"Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome","volume":"40","author":"Gangneux","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.jconrel.2007.10.027_bib197","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1128\/AAC.41.10.2089","article-title":"Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis","volume":"41","author":"Mullen","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.jconrel.2007.10.027_bib198","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Liposomal amphotericin B for the treatment of visceral leishmaniasis","volume":"43","author":"Bern","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib199","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1179\/000349803225002606","article-title":"Treatment of leishmaniasis in HIV-positive patients","volume":"97","author":"Laguna","year":"2003","journal-title":"Ann. Trop. Med. Parasitol."},{"issue":"2","key":"10.1016\/j.jconrel.2007.10.027_bib200","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1472-8206.2003.00168.x","article-title":"Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients","volume":"17","author":"Minodier","year":"2003","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib201","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00003495-199855040-00008","article-title":"Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis","volume":"55","author":"Coukell","year":"1998","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib202","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/clinids\/17.4.625","article-title":"Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus","volume":"17","author":"Torre-Cisneros","year":"1993","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.jconrel.2007.10.027_bib203","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.qco.0000191508.48481.f4","article-title":"Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis","volume":"18","author":"Barratt","year":"2005","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib204","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0166-3542(02)00128-6","article-title":"Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model","volume":"56","author":"Fraternale","year":"2002","journal-title":"Antiviral Res."},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib205","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1023\/A:1015852732512","article-title":"Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting","volume":"9","author":"Schafer","year":"1992","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib206","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10611860600942178","article-title":"Recent advances in delivery systems for anti-HIV1 therapy","volume":"15","author":"Lanao","year":"2007","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib207","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0163-7827(01)00019-4","article-title":"Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy","volume":"41","author":"Raulin","year":"2002","journal-title":"Prog. Lipid. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2007.10.027_bib208","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/psc.587","article-title":"Tuftsin\u2013AZT conjugate: potential macrophage targeting for AIDS therapy","volume":"11","author":"Fridkin","year":"2005","journal-title":"J. Pept. Sci.;"},{"issue":"3","key":"10.1016\/j.jconrel.2007.10.027_bib209","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1365-2362.2001.00806.x","article-title":"New drug combinations for the treatment of murine AIDS and macrophage protection","volume":"31","author":"Fraternale","year":"2001","journal-title":"Eur. J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.jconrel.2007.10.027_bib210","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/jac\/dkg428","article-title":"Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections","volume":"52","author":"Fraternale","year":"2003","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365907006207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365907006207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T01:29:22Z","timestamp":1708392562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365907006207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":210,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0168365907006207"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2007.10.027","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}